329 related articles for article (PubMed ID: 23566295)
21. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
Hachulla É
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
23. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
24. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
25. Rituximab treatment in lupus nephritis--where do we stand?
Gunnarsson I; Jonsdottir T
Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
[TBL] [Abstract][Full Text] [Related]
27. B cell biomarkers of rituximab responses in systemic lupus erythematosus.
Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
Arthritis Rheum; 2011 Oct; 63(10):3038-47. PubMed ID: 21618204
[TBL] [Abstract][Full Text] [Related]
28. SLE - Rituximab in lupus.
Eisenberg R
Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
[TBL] [Abstract][Full Text] [Related]
29. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
[TBL] [Abstract][Full Text] [Related]
31. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
32. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
[TBL] [Abstract][Full Text] [Related]
33. Rituximab - shadow, illusion or light?
van Vollenhoven RF
Autoimmun Rev; 2012 Jun; 11(8):563-7. PubMed ID: 22036829
[TBL] [Abstract][Full Text] [Related]
34. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.
Watson L; Beresford MW; Maynes C; Pilkington C; Marks SD; Glackin Y; Tullus K
Lupus; 2015 Jan; 24(1):10-7. PubMed ID: 25117653
[TBL] [Abstract][Full Text] [Related]
35. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies.
Leone A; Sciascia S; Kamal A; Khamashta M
Expert Rev Clin Immunol; 2015 Jan; 11(1):109-16. PubMed ID: 25511179
[TBL] [Abstract][Full Text] [Related]
36. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.
Fattah Z; Isenberg DA
Expert Opin Biol Ther; 2014 Mar; 14(3):311-26. PubMed ID: 24387632
[TBL] [Abstract][Full Text] [Related]
37. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
Hui-Yuen JS; Nguyen SC; Askanase AD
Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
[TBL] [Abstract][Full Text] [Related]
38. B-cell-depleting therapy in systemic lupus erythematosus.
Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
[TBL] [Abstract][Full Text] [Related]
39. B-cell depletion and repopulation in autoimmune diseases.
Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
[TBL] [Abstract][Full Text] [Related]
40. Rituximab therapy for juvenile-onset systemic lupus erythematosus.
Nwobi O; Abitbol CL; Chandar J; Seeherunvong W; Zilleruelo G
Pediatr Nephrol; 2008 Mar; 23(3):413-9. PubMed ID: 18097688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
